International Journal of Radiation Oncology*Biology*Physics
RAPID COMMUNICATIONAmerican Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for 103palladium brachytherapy
Introduction
Recently, there have been three important developments in palladium-103 (103Pd) brachytherapy dosimetry. First, several changes have been noted in apparent activity quoted by the manufacturer over the past several years (1). Second, in January 1999, the National Institute of Standards and Technology (NIST) implemented an air-kerma strength (Sk) standard for 103Pd brachytherapy sources (1). Lastly, there has been a change in the dose rate constant for 103Pd 2, 3. These developments mandate a reevaluation of 103Pd brachytherapy prescribing practices.
Section snippets
Methods and materials
During the Annual Meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO) in November 1999, the American Brachytherapy Society (ABS), in cooperation with ASTRO, presented an informational symposium on recent issues relating to the NIST-1999 standard. Guided by the symposium audience comments and concerns, the Clinical Research Committee of the ABS convened a consensus session January 8–9, 2000 of brachytherapists and physicists to develop recommendations regarding future
Results
Since the introduction of 103Pd sources (Theragenics Corp., Norcross, GA) in 1987, the air kerma strength of 103Pd sources has been determined using a NIST traceable 109Cd source. Over the first 10 years, this standard, developed and maintained by the manufacturer, was consistent and stable to within about 2%. When the 109Cd source was changed in 1997, a 9% shift in the standard was noticed. The dose implications of this change were not fully determined until late 1999, when the AAPM developed
Conclusions
Due to the above considerations, the ABS recommends that the following be implemented for 103Pd dosimetry:
- 1.
All practicing physicians, physicists, dosimetrists, and suppliers immediately implement NIST-1999 air-kerma strength standard for 103Pd brachytherapy.
- 2.
All treatment planning systems and dose calculation algorithms must be updated to reflect new dose rate constants. The AAPM-recommended value for Theraseed model 200 is 0.665 cGy h−1 U−1. The dose rate constant for the Mentor MED3633 seed is
References (17)
- et al.
Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma
Int J Radiat Oncol Biol Phys
(1999) - et al.
103Pd brachytherapy and external beam irradiation for clinically localized, high risk prostatic carcinoma
Int J Radiat Oncol Biol Phys
(1996) - et al.
Transperineal palladium-103 prostate brachytherapyAnalysis of morbidity and seed migration
Urology
(1995) - et al.
Outpatient ultrasound-guided palladium-103 brachytherapy for localized adenocarcinoma of the prostateA preliminary report of 434 patients
Urology
(1998) - et al.
Rectal dosimetric analysis following prostate brachytherapy
Int J Radiat Oncol Biol Phys
(1999) - et al.
American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer
Int J Radiat Oncol Biol Phys
(1999) - Williamson J, Coursey B, DeWerd L; et al. Recommendations of the American Association of Physicists in Medicine on...
- Nath R, Yue N, Shahnazi K; et al. Measurement of dose-rate constant for 103Pd seeds with air-kerma strength calibration...
Cited by (77)
The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancer
2017, BrachytherapyCitation Excerpt :Based on available data the following recommendations are made for dose prescriptions. For patients with low risk or favorable disease treated by monotherapy, the prescription dose ranges from 110 to 125 Gy for palladium-103 and 140 to 160 Gy for iodine-125 (40–42). In recent years there has been experience with cesium-131, and if that isotope is used, reference to current literature is advised.
Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer
2012, International Journal of Radiation Oncology Biology PhysicsPredictors of metastatic disease after prostate brachytherapy
2012, International Journal of Radiation Oncology Biology Physics